Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.95EUR
−93.48 MEUR
698.35 KEUR
43.14 M
About CELLECTIS
Sector
CEO
André Choulika
Headquarters
Paris
Website
Employees (FY)
221
Founded
1999
ISIN
FR0010425595
FIGI
BBG000BFWRX2
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ZVA is 2.42 EUR — it has decreased by 0.82% in the past 24 hours. Watch CELLECTIS SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CELLECTIS SA stocks are traded under the ticker ZVA.
ZVA stock has fallen by 7.65% compared to the previous week, the month change is a 0.63% rise, over the last year CELLECTIS SA has showed a 28.53% increase.
We've gathered analysts' opinions on CELLECTIS SA future price: according to them, ZVA price has a max estimate of 9.25 EUR and a min estimate of 2.77 EUR. Watch ZVA chart and read a more detailed CELLECTIS SA stock forecast: see what analysts think of CELLECTIS SA and suggest that you do with its stocks.
ZVA stock is 1.46% volatile and has beta coefficient of 5.20. Track CELLECTIS SA stock price on the chart and check out the list of the most volatile stocks — is CELLECTIS SA there?
Today CELLECTIS SA has the market capitalization of 172.92 M, it has decreased by 7.88% over the last week.
Yes, you can track CELLECTIS SA financials in yearly and quarterly reports right on TradingView.
CELLECTIS SA is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
ZVA earnings for the last quarter are −0.14 EUR per share, whereas the estimation was −0.31 EUR resulting in a 55.02% surprise. The estimated earnings for the next quarter are −0.25 EUR per share. See more details about CELLECTIS SA earnings.
CELLECTIS SA revenue for the last quarter amounts to 6.01 M EUR despite the estimated figure of 3.46 M EUR. In the next quarter revenue is expected to reach 3.26 M EUR.
ZVA net income for the last quarter is 5.20 M EUR, while the quarter before that showed −39.86 M EUR of net income which accounts for 113.05% change. Track more CELLECTIS SA financial stats to get the full picture.
No, ZVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 221.00 employees. See our rating of the largest employees — is CELLECTIS SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLECTIS SA EBITDA is −78.88 M EUR, and current EBITDA margin is −11.67 K%. See more stats in CELLECTIS SA financial statements.
Like other stocks, ZVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLECTIS SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELLECTIS SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELLECTIS SA stock shows the sell signal. See more of CELLECTIS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.